In response to a Congressional mandate, the National Research Council conducted a review of the Small Business Innovation Research Program (SBIR) at the five federal agencies with SBIR programs with budgets in excess of $100 million (DOD, NIH, NASA, DOE, and NSF). The project was designed to answer questions of program operation and effectiveness, including the quality of the research projects being conducted under the SBIR program, the commercialization of the research, and the program's contribution to accomplishing agency missions. This report summarizes the presentations at a symposium exploring the effectiveness of Phase III of the SBIR program (the commercialization phase), during which innovations funded by Phase II awards move from the laboratory into the marketplace. No SBIR funds support Phase III; instead, to commercialize their products, small businesses are expected to garner additional funds from private investors, the capital markets, or from the agency that made the initial award.
The Small Business Innovation Research (SBIR) program is one of the largest examples of U.S. public-private partnerships. Founded in 1982, SBIR was designed to encourage small business to develop new processes and products and to provide quality research in support of the many missions of the U.S. government, including health, energy, the environment, and national defense. In response to a request from the U.S. Congress, the National Research Council assessed SBIR as administered by the five federal agencies that together make up 96 percent of program expenditures. This book, one of six in the series, reports on the SBIR program at the National Science Foundation. The study finds that the SBIR program is sound in concept and effective in practice, but that it can also be improved. Currently, the program is delivering results that meet most of the congressional objectives, including stimulating technological innovation, increasing private-sector commercialization of innovations, using small businesses to meet federal research and development needs, and fostering participation by minority and disadvantaged persons. The book suggests ways in which the program can improve operations, continue to increase private-sector commercialization, and improve participation by women and minorities.
In response to a Congressional mandate, the National Research Council conducted a review of the Small Business Innovation Research Program (SBIR) at the five federal agencies with SBIR programs with budgets in excess of $100 million (DOD, NIH, NASA, DOE, and NSF). The project was designed to answer questions of program operation and effectiveness, including the quality of the research projects being conducted under the SBIR program, the commercialization of the research, and the program's contribution to accomplishing agency missions. This report summarizes the presentations at a symposium exploring the effectiveness of Phase III of the SBIR program (the commercialization phase), during which innovations funded by Phase II awards move from the laboratory into the marketplace. No SBIR funds support Phase III; instead, to commercialize their products, small businesses are expected to garner additional funds from private investors, the capital markets, or from the agency that made the initial award.
As an authoritative guide to biotechnology enterprise and entrepreneurship, Biotechnology Entrepreneurship and Management supports the international community in training the biotechnology leaders of tomorrow. Outlining fundamental concepts vital to graduate students and practitioners entering the biotech industry in management or in any entrepreneurial capacity, Biotechnology Entrepreneurship and Management provides tested strategies and hard-won lessons from a leading board of educators and practitioners. It provides a 'how-to' for individuals training at any level for the biotech industry, from macro to micro. Coverage ranges from the initial challenge of translating a technology idea into a working business case, through securing angel investment, and in managing all aspects of the result: business valuation, business development, partnering, biological manufacturing, FDA approvals and regulatory requirements. An engaging and user-friendly style is complemented by diverse diagrams, graphics and business flow charts with decision trees to support effective management and decision making. - Provides tested strategies and lessons in an engaging and user-friendly style supplemented by tailored pedagogy, training tips and overview sidebars - Case studies are interspersed throughout each chapter to support key concepts and best practices. - Enhanced by use of numerous detailed graphics, tables and flow charts
Government acts as entrepreneur when its involvement in market activities is both innovative and characterized by entrepreneurial risk. Thinking of government as entrepreneur is a unique lens through which the authors of this book examine a specific subset of U.S. government policy actions. As such, their viewpoint underscores the purposeful intent of government, its ability to act in new and innovative ways, and its willingness to undertake policy actions that have uncertain outcomes. Viewing particular policy actions through an entrepreneurial lens is useful in two broad dimensions. First, it underscores the forward looking nature of policy makers as well as the need to evaluate the social outputs and outcomes of their behavior in terms of broad spillover impacts. Second, government acting as entrepreneur parallels in concept similar activities that occur in the private sector. Government as Entrepreneur is the first broad effort to emphasize the entrepreneurial aspects of governments. It is also the first systematic treatment of U.S. innovation policies to promote the formation of strategic research partnerships. It will foster a new perspective on the role of government and how incentives for government to act entrepreneurially might be institutionalized; it will serve as a vehicle for policy makers and scholars to think about the entrepreneurial actors in an economy, in a new way.
A Triple Helix of university-industry-government interactions is the key to innovation in increasingly knowledge-based societies. As the creation, dissemination, and utilization of knowledge moves from the periphery to the center of industrial production and governance, the concept of innovation, in product and process, is itself being transformed. In its place is a new sense of 'innovation in innovation' - the restructuring and enhancement of the organizational arrangements and incentives that foster innovation. This triple helix intersection of relatively independent institutional spheres generates hybrid organizations such as technology transfer offices in universities, firms, and government research labs and business and financial support institutions such as angel networks and venture capital for new technology-based firms that are increasingly developing around the world. The Triple Helix describes this new innovation model and assists students, researchers, and policymakers in addressing such questions as: How do we enhance the role of universities in regional economic and social development? How can governments, at all levels, encourage citizens to take an active role in promoting innovation in innovation and, conversely, how can citizens so encourage their governments? How can firms collaborate with each other and with universities and government to become more innovative? What are the key elements and challenges to reaching these goals?
Medical Innovation: Concept to Commercialization is a practical, step-by-step approach on how to move a novel concept through development to realize a commercially successful product. Real-world experience cases and knowledgeable contributors provide lessons that cover the practices of diverse organizations and multiple products. This important reference will help improve success and avoid innovation failure for translational researchers, entrepreneurs, medical school educators, biomedical engineering students and faculty, and aspiring physicians.
The recent momentum and urgency around translating science and technology into health innovation is inspiring. It is transforming academia, too, as the rapidly-evolving world of health innovation has given rise to a new breed of academic - the academic entrepreneur - who works to move ideas from initial research to practical implementation. The work of these individuals is crucial to realizing the potential of investments in better care, and yet there existed no central repository for information and wisdom relevant to their mission; no place to house and explore the evolving knowledge base around translating evidence into impact.We aim to build one. In the spirit of collaboration, the Children's Hospital of Philadelphia (CHOP) Research Institute collaborated with the University of Pennsylvania's (Penn) Institute for Translational Medicine and Therapeutics (ITMAT) to seed fund a grassroots effort of editors, subject matter experts, and translational research students to create a free open education resource stored on ScholarlyCommons (University of Pennsylvania, Philadelphia, PA).Academic Entrepreneurship seeks to build a diverse community of empowered professionals who know how to bridge the worlds of academic research and commercialization to turn ideas and discoveries into innovations that provide value to patients, providers, and healthcare systems, thereby realizing full market potential and societal impact. This book is a repository of tools, advice, and best practices that establishes a foundation for academic researchers and innovators wherever they may reside.Recognizing that academic entrepreneurs are busy and bright, and have limited time to learn entrepreneurship, the chapters in this book were designed as an efficient and state-of-the-art source of guidance. With carefully curated content as a strong foundation, the reader will have quick introductions to key topics in academic entrepreneurship and innovations with a list of resources for those who wish to go further.This book was created as a limited print run of the first edition of the living content stored in the University of Pennsylvania's open access repository, ScholarlyCommons, as of 1/1/2020. As a living e-textbook, the content of Academic Entrepreneurship for Medical and Health Scientists is continuously enhanced and revised.
The Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) programs provide grant funding to help companies commercialize transformative technologies. Companies that successfully receive Phase I awards are eligible to apply for Phase II grants that can generate over a million dollars to fund product development. This book provides a straightforward, user-friendly approach to preparing a Phase II application for the National Institutes of Health (NIH) SBIR/STTR programs. A 12-week strategy is presented for developing a strong Commercialization Plan, Research Plan, and Other Components that are required for a successful application. In addition, the Review and Award process, as well as post-award considerations, are described. The Eva Garland Consulting team provides deep expertise in developing competitive SBIR/STTR proposals, having successfully assisted clients who have collectively received hundreds of millions of dollars of SBIR/STTR funding.
This book provides a straightforward, user-friendly approach for preparing a NIH Phase I SBIR/STTR application. The proposal preparation process is spread over a 10-week period, and tasks are completed in a logical progression. The time requirement ranges from 10 to 25 hours per week, leaving sufficient time for other business activities. Dr. Garland draws on her years of SBIR/STTR proposal preparation experience, providing useful tips to ensure your application is highly competitive and that the entire preparation process proceeds smoothly.
